新发转移性透明细胞肾细胞癌的治疗选择:当前推荐与未来展望
本文以一位73岁中危寡转移性透明细胞肾细胞癌患者为例,讨论基于指南的系统治疗选择。内容涵盖减瘤性肾切除术、转移灶定向治疗及多种靶向与免疫联合方案,并结合最新进展展望未来治疗路径。
要点
- 以临床病例为线索梳理新发转移性透明细胞肾癌的指南推荐治疗。
- 讨论减瘤性肾切除术与转移灶定向治疗在寡转移患者中的角色。
- 汇总系统靶向与免疫治疗的多重选择并展望未来方向。
核心结论
- 新发转移性透明细胞肾细胞癌存在多种治疗选择,需基于指南并结合病例特征个体化决策。
研究设计与样本
- 临床病例为基础的讨论:1例73岁男性中危寡转移性透明细胞肾细胞癌患者,接受系统治疗。
主要发现
- 讨论涵盖减瘤性肾切除术、转移灶定向治疗及系统靶向与免疫治疗的多重选择。
- 结合最新科学进展,展望未来可能影响治疗路径的发展方向。
关键数值与推荐
- 患者为73岁男性,中危寡转移性透明细胞肾细胞癌,接受系统治疗。
临床怎么用
- 临床可参考本文梳理的指南推荐,为寡转移性透明细胞肾癌患者制定系统治疗与局部治疗组合方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This clinical case-based discussion focuses on a 73-yr-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with systemic therapy. Current guideline-based treatment options are presented and critically examined. The discussion covers the main aspects of the management of metastatic RCC, such as the role of cytoreductive nephrectomy and metastasis-directed therapies, as well as the multiple options for systemic targeted and immune therapies. An insight into developments that may play a role in treatment pathways in the future according to the latest scientific advances is also provided. PATIENT SUMMARY: A number of treatment options are available for patients who have metastatic disease when diagnosed with clear-cell kidney cancer. Starting from a clinical case, the current standard of care and future perspectives regarding treatment of this disease are presented.
引用
- Benamran D, Albiges L, Bex A, et al. Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights. Eur Urol Oncol. 2021. PMID: 34531172. doi:10.1016/j.euo.2021.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。